ArticleBreast cancer research and treatment2023
Radiofrequency localization of nonpalpable breast cancer in a multicentre prospective cohort study: feasibility, clinical acceptability, and safety.
Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Radiofrequency identification tag localization of nonpalpable breast lesions: a systematic review and meta-analysis.European radiology experimental · 2025Pooled it
- Magnetic seed versus guidewire-based breast cancer localization with magnetic lymph node detection: cost-minimization analysis.The British journal of surgery · 2025Trial
- Physics-Informed Design and Bench/Phantom Validation of a Shaft-Compatible 13.56 MHz NFC System for Laparoscopic Colorectal Tumour Localisation.Sensors (Basel, Switzerland) · 2026Article
- Bracketed Lumpectomy: A Comparison of Radiofrequency Identification Tag Localization to Wire Localization.Annals of surgical oncology · 2026Article
- RFID Technology for Intraoperative Localisation of Small Colorectal Tumours: Electromagnetic Analysis and Experimental Validation.Diagnostics (Basel, Switzerland) · 2026Article
- Observational
- The Era "or Error" of Second Localization Procedures.The breast journal · 2025Article
- Early Breast Cancer: Could Combined LOCalizerJournal of clinical medicine · 2024Article
- Evolution of localization methods for non-palpable breast lesions: a literature review from a translational medicine perspective.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2024Review
- Efficacy of the Radiofrequency Identification Technique in Breast Cancer Patients: A Single Institution Retrospective Study.European journal of breast health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
purposeIn breast conserving surgery, accurate lesion localization is essential for obtaining adequate surgical margins. Preoperative wire localization (WL) and radioactive seed localization (RSL) are widely accepted methods to guide surgical excision of nonpalpable breast lesions but are limited by logistical challenges, migration issues, and legislative complexities. Radiofrequency identification (RFID) technology may offer a viable alternative. The purpose of this study was to evaluate the feasibility, clinical acceptability, and safety of RFID surgical guidance for localization of nonpalpable breast cancer.
methodsIn a prospective multicentre cohort study, the first 100 RFID localization procedures were included. The primary outcome was the percentage of clear resection margins and re-excision rate. Secondary outcomes included procedure details, user experience, learningcurve, and adverse events.
resultsBetween April 2019 and May 2021, 100 women underwent RFID guided breast conserving surgery. Clear resection margins were obtained in 89 out of 96 included patients (92.7%), re-excision was indicated in three patients (3.1%). Radiologists reported difficulties with the placement of the RFID tag, partially related to the relatively large needle-applicator (12-gauge). This led to the premature termination of the study in the hospital using RSL as regular care. The radiologist experience was improved after a manufacturer modification of the needle-applicator. Surgical localization involved a low learning curve. Adverse events (n = 33) included dislocation of the marker during insertion (8%) and hematomas (9%). The majority of adverse events (85%) occurred using the first-generation needle-applicator.
conclusionRFID technology is a potential alternative for non-radioactive and non-wire localization of nonpalpable breast lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.